111, Inc.
YIHealthcareNASDAQMedical Distribution
Scan Results
Daily timeframe111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. Valued at $30.5M, YI is a micro-cap name in its sector. It operates through two segments, B2C and B2B.
Market Cap
$30.5M
Beta
0.65
P/E (TTM)
—
P/E (Fwd)
24.75
EPS (TTM)
$-7.68
EPS (Fwd)
$0.14
ROE
-14.8%
ROA
-0.6%
Cash
$366.2M
Total Debt
$283.9M
Free CF
-$80.0M
52W Change
-41.4%
Annual Financials
Cash vs Debt
Where YI stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, YI finished 37.07% below its 150-day moving average ($5.53) and 31.90% below its 200-day moving average ($5.11). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is YI overbought or oversold?
At the September 3, 2026 close, YI's RSI(14) was 39.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $366.2M in cash and $283.9M in debt, YI maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$80.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -14.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $13.52B (2022) to $12.56B (2025).
The relatively low beta of 0.65 suggests YI is a less volatile holding compared to the broader index. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence 111, Inc.'s trajectory.